ClinicalTrials.gg
CompletedNCT04626518Updated Sep 25, 2026

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

A Phase 1/2 interventional study of Pembrolizumab and MK-4830 in Carcinoma, Renal Cell, sponsored by Merck Sharp & Dohme LLC. Completed at 51 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing belzutifan in Carcinoma, Renal Cell — 5 open to participants now, 13 under way, 5 of them phase 3. belzutifan · Carcinoma, Renal Cell.

Enrollment
6th of 18
263 · median 135
Started
2020
with 4 others
Phase 1/2
2 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
10 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing belzutifan in Carcinoma, Renal Cell, this one is the 6th largest by enrollment, is one of 5 that started in 2020, is one of 2 in phase 1/2, and was the 7th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 18 studies testing belzutifan in Carcinoma, Renal Cell are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About belzutifan

belzutifan: first FDA approval 2021 (WELIREG), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing belzutifan in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).

The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC).

This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • receptor tyrosine kinase inhibitor
  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of locally advanced/ clear cell renal cell carcinoma (ccRCC)
  • Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a programmed cell death ligand 1 (PD-(L)1) (in sequence or in combination with a vascular endothelial growth factor. - tyrosine kinase inhibitor [VEGF-TKI]) where PD-(L)1 checkpoint inhibitor treatment progression is defined by meeting ALL of the following criteria: (a) has received ≥2 doses of an anti-PD-(L)1 monoclonal antibody (mAb) (b) has shown radiographic disease progression during or after an anti-PD-(L)1 mAb as defined by version 1.1 (RECIST 1.1) by investigator (c) disease progression has been documented within 12 weeks from the last dose of an anti-PD-(L)1 mAb
  • Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a VEGF-TKI (in sequence or in combination with a PD-[L]1 checkpoint inhibitor) where VEGF-TKI treatment progression is defined by meeting the following criterion: has shown radiographic disease progression during or after a treatment with a VEGF-TKI as defined by RECIST 1.1 by investigator.
  • Is able to swallow oral medication
  • Has adequate organ function
  • Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks before randomization/allocation
  • Has resolution of toxic effects of prior therapy to ≤Grade 1
  • Has adequately controlled blood pressure (BP ≤150/90 mm Hg) with no change in hypertensive medications within 1 week before randomization/allocation
  • Male participants are abstinent from heterosexual intercourse or agree to use during treatment with and for at least 7 days after the last dose of lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped, if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, MK-4830 or a combination of the aforementioned drugs, no contraception is needed
  • Female participant is not pregnant or breastfeeding and is not a woman of (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, MK-4830 or 30 days after the last dose of lenvatinib or belzutifan, whichever occurs last and must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention

Exclusion criteria

Exclusion Criteria:

  • Has urine protein ≥1 g/24 hours and has any of the following: (a) a pulse oximeter reading \<92% at rest, or (b) requires intermittent supplemental oxygen, or (c) requires chronic supplemental oxygen (d) active hemoptysis within 3 weeks prior to the first dose of study intervention
  • Has cardiovascular disease within 12 months from the first dose of study intervention administration
  • Has had major surgery within 3 weeks before first dose of study interventions
  • Has a history of lung disease
  • Has a history of inflammatory bowel disease
  • Has preexisting gastrointestinal (GI) or non-GI fistula
  • Has malabsorption due to prior GI surgery or disease
  • Has previously received treatment with a combination of pembrolizumab plus lenvatinib
  • Has received prior treatment with belzutifan
  • Has received prior radiotherapy within 2 weeks of start of study intervention
  • Has received a live or within 30 days before the first dose of study intervention; killed vaccines are allowed
  • Has received more than 4 previous systemic anticancer treatment regimens
  • Has a diagnosis of immunodeficiency or is receiving any form of therapy within 7 days prior to the first dose of study intervention
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has known central nervous system (CNS) and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Coformulation Pembrolizumab/Quavonlimab

    Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to \~2 years).

    Biological: Pembrolizumab/Quavonlimab

  • Experimental
    Coformulation Favezelimab/Pembrolizumab

    Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).

    Biological: Favezelimab/Pembrolizumab

  • Experimental
    Pembrolizumab + MK-4830

    Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to \~2 years).

    Biological: Pembrolizumab · Biological: MK-4830

  • Experimental
    Pembrolizumab + Belzutifan

    Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.

    Biological: Pembrolizumab · Drug: Belzutifan

  • Experimental
    Belzutifan + Lenvatinib

    Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.

    Drug: Belzutifan · Drug: Lenvatinib

  • Experimental
    Pembrolizumab + Lenvatinib

    Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.

    Biological: Pembrolizumab · Drug: Lenvatinib

Interventions

  • BiologicalPembrolizumab

    Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

    Also known as: MK-3475, KEYTRUDA®

  • BiologicalMK-4830

    Administered via IV infusion at a dose of 800 mg Q3W

  • Administered via oral tablet at a dose of 120 mg QD

    Also known as: MK-6482, WELIREG™

  • Administered via oral capsule at a dose of 20 mg QD

    Also known as: MK-7902, E7080, LENVIMA®

  • BiologicalPembrolizumab/Quavonlimab

    Drug page: Pembrolizumab/Quavonlimab MK-1308A

    Administered via IV infusion at a dose of 400 mg/25 mg Q6W

    Also known as: MK-1308A

  • BiologicalFavezelimab/Pembrolizumab

    Drug pages: Favezelimab · Pembrolizumab

    Administered via IV infusion at a dose of 800 mg/200 mg Q3W

    Also known as: MK-4280A

06

What researchers measure

Primary outcomes

  1. Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)

    DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting \>7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for \>1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for \>14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the safety lead-in phase will be presented.

    Time frame: Up to ~21 days

  2. Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the safety lead-in phase will be presented.

    Time frame: Up to ~21 days

  3. Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the safety lead-in phase will be presented.

    Time frame: Up to ~21 days

  4. Efficacy Phase: Number of participants who experienced DLTs

    DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting \>7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for \>1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for \>14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the efficacy phase will be presented.

    Time frame: Up to ~21 days

  5. Efficacy Phase: Number of participants who experience one or more AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the efficacy phase will be presented.

    Time frame: Up to ~56 months

  6. Efficacy Phase: Number of participants who discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the efficacy phase will be presented.

    Time frame: Up to ~56 months

  7. Efficacy Phase: Objective response rate (ORR)

    ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

    Time frame: Up to ~56 months

Secondary outcomes

  1. Efficacy Phase: Duration of response (DOR)

    For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1.

    Time frame: Up to ~56 months

  2. Efficacy Phase: Progression-free survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 by BICR.

    Time frame: Up to ~56 months

  3. Efficacy Phase: Overall survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to ~56 months

  4. Efficacy Phase: Clinical benefit rate (CBR)

    CBR is defined as the percentage of participants who have achieved CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease) of ≥6 months. Responses are according to RECIST 1.1 by BICR.

    Time frame: Up to ~56 months

07

Study locations

51 sites
  • University of California at San Francisco ( Site 3008)
    San Francisco, California 94158, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011)
    New Haven, Connecticut 06510, United States
  • University of Chicago ( Site 3013)
    Chicago, Illinois 60637, United States
  • University of Iowa ( Site 3012)
    Iowa City, Iowa 52242, United States
  • Henry Ford Health System ( Site 3014)
    Detroit, Michigan 48202, United States
  • Laura and Isaac Perlmutter Cancer Center ( Site 3016)
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center ( Site 3002)
    New York, New York 10065, United States
  • Duke Cancer Institute ( Site 3015)
    Durham, North Carolina 27710, United States
  • UPMC Cancer Center/Hillman Cancer Center ( Site 3017)
    Pittsburgh, Pennsylvania 15232, United States
  • Vanderbilt University Medical Center ( Site 3004)
    Nashville, Tennessee 37232, United States
  • UTSW Medical Center ( Site 3003)
    Dallas, Texas 75390, United States
  • Blacktown Hospital ( Site 3601)
    Blacktown, New South Wales 2148, Australia
  • St George Hospital ( Site 3602)
    Kogarah, New South Wales 2217, Australia
  • Royal Brisbane and Women's Hospital ( Site 3603)
    Herston, Queensland 4029, Australia
  • Austin Health ( Site 3600)
    Melbourne, Victoria 3084, Australia
  • Princess Margaret Cancer Centre ( Site 3101)
    Toronto, Ontario M5G 1Z5, Canada
  • Jewish General Hospital ( Site 3100)
    Montreal, Quebec H3T 1E2, Canada
  • James Lind Centro de Investigacion del Cancer ( Site 4108)
    Temuco, Araucania 4800827, Chile
  • CIDO SpA-Oncology ( Site 4106)
    Temuco, Araucania 4810148, Chile
  • FALP-UIDO ( Site 4100)
    Santiago, Region M. de Santiago 7500921, Chile
  • Bradfordhill-Clinical Area ( Site 4101)
    Santiago, Region M. de Santiago 8420383, Chile
  • ONCOCENTRO APYS-ACEREY ( Site 4103)
    Viña del Mar, Valparaiso 2520598, Chile
  • Institut De Cancerologie De Lorraine ( Site 3204)
    Vandœuvre-lès-Nancy, Ain 54519, France
  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203)
    Strasbourg, Alsace 67200, France
  • Institut Claudius Regaud ( Site 3200)
    Toulouse, Haute-Garonne 31059, France
  • Gustave Roussy ( Site 3202)
    Villejuif, Île-de-France Region 94800, France
  • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301)
    Budapest, Pest County 1122, Hungary
  • Rambam Health Care Campus-Oncology Division ( Site 3500)
    Haifa, 3109601, Israel
  • Hadassah Medical Center-Oncology ( Site 3504)
    Jerusalem, 9112001, Israel
  • Rabin Medical Center ( Site 3502)
    Petah Tikva, 4941492, Israel
  • Sheba Medical Center - Oncology Division ( Site 3501)
    Ramat Gan, 52621, Israel
  • Sourasky Medical Center ( Site 3503)
    Tel Aviv, 6423906, Israel
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402)
    Amsterdam, North Holland 1066 CX, Netherlands
  • Erasmus Medisch Centrum ( Site 4401)
    Rotterdam, South Holland 3015 GD, Netherlands
  • Auckland City Hospital ( Site 3700)
    Auckland, 1023, New Zealand
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200)
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Asan Medical Center ( Site 3800)
    Songpagu, Seoul 05505, South Korea
  • Severance Hospital ( Site 3802)
    Seoul, 03722, South Korea
  • Samsung Medical Center ( Site 3801)
    Seoul, 06351, South Korea
  • Hospital Universitari Vall d Hebron ( Site 3300)
    Barcelona, Catalonia 08035, Spain
  • Hospital Universitario Ramon y Cajal ( Site 3301)
    Madrid, 28034, Spain
  • Southampton General Hospital ( Site 3403)
    Southampton, England SO16 6YD, United Kingdom
  • The Beatson West of Scotland Cancer Centre ( Site 3405)
    Glasgow, Glasgow City G12 0YN, United Kingdom
  • Royal Preston Hospital ( Site 3406)
    Preston, Lancashire PR2 9HT, United Kingdom
  • Leicester Royal Infirmary ( Site 3408)
    Leicester, Leicestershire LE1 5WW, United Kingdom
  • Barts Health NHS Trust ( Site 3401)
    London, London, City of EC1A 7BE, United Kingdom
  • Western General Hospital ( Site 3402)
    Edinburgh, Midlothian EH4 2XU, United Kingdom
  • Velindre Cancer Centre Hospital ( Site 3407)
    Cardiff, Wales CF14 2TL, United Kingdom
  • The Christie NHS Foundation Trust ( Site 3400)
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2026, 67 months.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 67 months is close to that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Aug 2026 → Jul 2026 and completion Aug 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2020
First posted
Nov 12, 2020
StartActual
Dec 17, 2020
Primary completionActual
Jul 23, 2026was Aug 2026
CompletionActual
Jul 23, 2026was Aug 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Primary completion
Aug 21, 2026→Jul 23, 2026 (actual)
Sep 25, 2026
Study completion
Aug 21, 2026→Jul 23, 2026 (actual)
Sep 25, 2026
Enrollment
370 (estimated)→263 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    Primary completion Aug 21, 2026→Jul 23, 2026 (now actual)
    Study completion Aug 21, 2026→Jul 23, 2026 (now actual)
    Enrollment 370 (estimated)→263 (actual)
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04626518
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Dec 17, 2020
Primary completion
Jul 23, 2026
Completion
Jul 23, 2026
Last update
Sep 25, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-ILT4 Monoclonal Antibody MK-4830 · Belzutifan · Pembrolizumab/Quavonlimab MK-1308A · Favezelimab · Pembrolizumab

Start the discussion